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Abstract 
Background. Esophageal cancer is ranked in the top ten of diagnosed tumors worldwide. Even though 
improvements in survival could be noticed over the last years, prognosis remains poor. ETS 
translocation variant 1 (ETV1) is a member of a family of transcription factors and is phosphorylated 
by mitogen-activated protein kinase (MAPK)-activated protein kinase 2 (MK2). Aim of this study was 
to evaluate the prognostic role of MK2 and ETV1 in esophageal cancer.  
Methods. Consecutive patients that underwent surgical resection at the department of surgery at the 
Medical University of Vienna between 1991 and 2012 were included into this study. After 
microscopic analysis, tissue micro arrays (TMAs) were created and immunohistochemistry was 
performed with antibodies against MK2 and ETV1.  
Results. 323 patients were included in this study. Clinical data was achieved from a prospective 
patient data base. Nuclear overexpression of MK2 was observed in 143 (44.3%) cases for nuclear 
staining and in 142 (44.0%) cases a cytoplasmic overexpression of MK2 was observed. Nuclear and 
cytoplasmic ETV1 overexpression was detected in 20 cases (6.2%) and 30 cases (9.3%), respectively. 
In univariate survival analysis, cMK2 and nETV1 were found to be significantly associated with 
patients’ overall survival. Whereas overexpression of cMK2 was associated with shorter, nETV1 
was associated with longer overall survival. In multivariate survival analysis, both cMK2 and nETV1 
were found to be independent prognostic factors for the subgroup of EAC as well.  
Discussion. Expression of MK2 and ETV1 are prognostic factors in patients, with esophageal 
adenocarcinoma. 
Key words: Esophageal Adenocarcinoma; Mitogen-activated protein kinase (MAPK)-activated protein kinase 2 
(MK2); ETS translocation variant 1 (ETV1) 
Introduction 
Even though improvements in diagnosis, 
surgical techniques and multimodal therapeutically 
approaches have led to significant improvement, 
prognosis for patients suffering from EC remain poor 
[1-3]. Therefore, it is important to investigate other, 
more effective molecular markers for the treatment of 
gastroesophageal cancers. The mitogen-activated 
protein kinase (MAPK)-activated protein kinase 2 
(MK2) is an intracellular mediator of stress and is 
stimulated by signals such as heat-shock and tumor 
necrosis factor α (TNF-α) mediated by the p38-MAP 
kinase pathway [4, 5]. MK2 is an important 
intracellular mediator of stress signals such as 
inflammation. Due to its role in regulation of 
cytokines, MK2 emerged as a possible 
anti-inflammatory target. It’s role in carcinogenesis 
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has been examined in a number of malignancies, but 
no data exists on its role in esophageal cancer until 
now.  
A variety of proteins are phosphorylated by 
MK2. Previously published data shows, that 
transcriptional activity (ETV1) can be stimulated by 
ERK-MAK kinases and ETV1 was identified as target 
of the protein kinase MK2 [6, 7]. 
Ets variant gene 1 (ETV1), also known as ER81, is 
a member of the E-twenty-six (ETS) family, one of the 
largest families of transcription factors and 
oncogenes. Beside its physiological functions it plays 
a major role in cell differentiation, is upregulated in a 
number of tumors and interact with many factors 
resulting in oncogenesis [8-11]. ETV1 has been found 
to cooperate with the p38 pathway and to promote 
tumor progression and metastasis in a number of 
human malignancies, upregulating matrix metallo-
proteinases (MMP) involved in tumor cell migration 
and invasion [6, 12, 13]. In prostate cancer, 
upregulation of MMP-7 (matrilysin) for example leads 
to an oncogenic effect of ETV1 [14, 15]. In melanoma 
genesis, a deregulation of ETV1 could be observed, 
implicating the pivotal lineage dependency mediated 
by ETS transcription factors [16]. 
Whereas the role of MK2 and ETV1 in 
gastrointestinal stromal tumors (GIST) were 
investigated intensively, little is known about the 
expression and the influence on survival of MK2 and 
ETV1 in gastroesophageal cancer [10, 17-19]. 
Material and Methods 
Patients collective  
This study was approved by the Ethics 
Committee of the Medical University of Vienna, 
Austria, and was conducted in accordance with the 
Declaration of Helsinki Principals. All patients 
included in this study underwent surgical resection of 
EC during the period from October 1991 to June 2012 
at the Department of Surgery, Medical University of 
Vienna. All tumors were restaged according to the 
UICC 7th edition TNM classification. Patients showing 
complete respond to neoadjuvant therapy (complete 
responders) and patients with distant metastasis at 
time of surgery were excluded from this study. 
Formalin-fixed, paraffin-embedded tissue blocks 
were established. Per case, two tissue cylinders with a 
2.0 mm diameter were punched from representative 
tissue areas. Histological types were confirmed by 
experienced pathologists (Figure 1). The TMA 
contained well-documented clinico-pathological data, 
including patients’ age, sex, tumor location, tumor 
differentiation, TNM staging and follow-up data.  
Immunohistochemistry 
Immunohistochemistry (IHC) was performed on 
paraffin-embedded specimens fixed in 4% buffered 
formalin, using 3µm thick histological sections. MK2 
expression was detected by using an anti-human 
MAPKAPK-2 rabbit polyclonal antibody (ab63574 
Cambridge, UK) in a dilution of 1:200. ETV1 
expression was detected by using a polyclonal rabbit 
anti-ER81 antibody (ab81086, Abcam, Cambridge, 
UK) in a dilution of 1:200. This antibody is active 
against a synthetic peptide, interacting with the C-end 
of the protein. In case of a gene translocation 
(hypothysing, that ER81 has a 5’ fusion-partner [20]) 
this antibody is able to detect an overexpression 
caused by these protein products. Staining was 
performed on a Benchmark Ultra Immunostainer 
(Roche Diagnostics, Basel, Switzerland). 
Immunohistochemistry for MK2 and ETV1 were 
validated as described previously [17, 18, 21, 22].  Two 
observers (S.F.S. and M.F.) independently reviewed 
all slides. Immunostaining scores of MK2 and ETV1 
(IHC score 0-300) were calculated as the semi 
quantitative products of the staining intensity (1 = 
weak, 2 = moderate or 3 = strong) and the rates of 
staining were given in percentages of tumor cells 
showing positive staining (0-100%). Tumors showing 
expression equal or below the median were 
considered as low or absent as described previously 
[23]. Analyzing the specimens, between cytoplasmic 
and nuclear staining intensity was discriminated.  A 
tumor specimen was considered as positive for the 
expression of MK2 and ETV1, when >90% of tumor 
cells showed cytoplasmic staining.  
Statistics 
Overall survival (OS) was defined as the time 
between primary surgery and the patients’ death. 
Death from cause other than gastric, gastroesophageal 
or esophageal cancer or survival until the end of the 
observation period was considered as censored 
observations. Disease free survival (DFS) was defined 
from the day of primary surgery until the first 
evidence of disease progression. The significance of 
differences in survival times were determined with a 
log-rank test. Uni- and multivariate analyses were 
performed with Cox proportional hazards models. 
Correlations between clinicopathological parameters 
and MK2 expression and ETV1 expression levels were 
analyzed with the χ2. A two-tailed Mann-Whitney U 
test was used as appropriate (to determine differences 
in continuous variables between the groups. i.e. in OS, 
DFS and age). p-values ≤0.05 were considered as 
significant. Statistical analysis was performed with 
the R statistical package [24, 25].  
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Figure 1. Kaplan-Meier curves of survival of esophageal cancer patients with cMK2 overexpression (high) compared with those with low/absent cMK2 expression. 
(A) Overall survival (OS) of all patients. (C) OS of patients with adenocarcinoma (AC). (E) OS of patients with squamous cell carcinoma (SCC). Kaplan-Meier curves 
of survival of esophageal cancer patients with nETV1 overexpression (high) compared with those with low/absent nETV1 expression. (B) OS of all patients. (D) OS of 
patients with AC. (F) OS of patients with SCC. 
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Results 
Finally, 323 patients were included in this study. 
The majority of patients 248 (77.8%) were male and 
the mean age at time of surgery was 65.8 (±10.6) years 
(standard deviation). 192 (59.4%) cases were 
adenocarcinomas (AC) and 131 (40.6%) squamous cell 
carcinomas (SCC). Seventy-three (22.6%) patients 
underwent neoadjuvant therapy (NT). 
After restaging all cases according to the UICC 
7th edition TNM classification, the majority of 
carcinomas were staged as (y)pT3 (170 cases, 52.6%), 
followed by stage (y)pT2 (80 cases, 24.8%), (y)pT1 (58 
cases, 17.9%) and (y)pT4 (15 cases, 4.7%). Beside the 
histological verified carcinomas, 19 cases of 
high-grade-dysplasia (HGD) were included into this 
study. 4 cases of HGD (21.1%) showed overexpression 
of cETV1, and in 6 cases of HGD (46.2%) we found 
cMK2 overexpressed (6 cases of HGD were not 
available for analysis due to technical problems). The 
majority of cases showed (y)N0 stage (111 cases, 
34.4%). 91 cases (28.2%) were staged as (y)N1, 61 cases 
(18.9%) as (y)N2 and 60 cases (18.5%) as (y)N3. 167 
(51.7%) of patients received adjuvant chemotherapy. 
Details for clinicopathological characteristics are 
shown in Table 1. 
Staining for MK2 was performed in 314 cases. 
Overexpression was observed in 143 (44.3%) cases for 
nuclear staining and in 142 (44.0%) cases of 
cytoplasmic staining. Due to technical problems, in 9 
(2.7%) cases no staining for nuclear and cytoplasmic 
MK2 expression was possible. 
Staining for ETV1 expression, was performed in 
323 cases. The majority of cases showed absent or low 
nuclear staining (303 cases, 87.2%), 20 cases (6.2%) 
were considered as positive. Analyzing the 
cytoplasmic staining intensity, 293 cases (90.7%) 
showed absent or low expression and 30 cases (9.3%) 
positive result.  
Detailed information on nuclear and cytoplasmic 
MK2 and ETV1 staining results are shown in Table 2. 
 
Table 1. Association of cMK2 expression and nETV1 expression with clinicopathologic parameters in patients with esophageal cancer. 
Factors  All  (n=323) cMK2 (n=314)    nETV1 (n=323)   
   (%)  high (%) low/absent (%) p-value  high (%) low/absent (%) p-value 
                
Age (SD)  65.8 (10.6)  65.3 (10.6)  66.0 (10.8)  >0.05  63.7 (11.1)  66.0 (10.6)  >0.05 
Sex         >0.05      >0.05 
Male  248 (76.8)  115 (36.6) 126 (40.1)   16 (5.0) 232 (71.8)  
Female  75 (23.2)  27 (8.6) 46 (14.6)   4 (1.2) 71 (22.0)  
Tumor Type        <0.001      >0.05 
AC  192 (59.4)  104 (33.1) 83 (26.4)   11 (3.4) 181 (56.0)  
SCC  131 (40.6)  38 (12.1) 89 (28.3)   9 (2.8) 122 (37.8)  
(y)pT         0.009      <0.001 
1  58 (17.9)  32 (10.2) 21 (6.7)   13 (4.0) 45 (13.9)  
2  80 (24.8)  24 (7.6) 54 (17.2)   2 (0.6) 78 (24.1)  
3  170 (52.6)  80 (25.5) 88 (28.0)   5 (1.5) 165 (51.1)  
4  15 (4.7)  6 (1.9) 9 (2.9)   0 (0.0) 15 (4.6)  
(y)pN         0.009      0.002 
0  111 (34.4)  38 (12.1) 66 (21.0)   14 (4.3) 97 (30.0)  
1  91 (28.2)  38 (12.1) 52 (16.6)   6  (1.9) 85 (26.3)  
2  61 (18.9)  28 (8.9) 32 (10.2)   0 (0.0) 61 (18.9)  
3  60 (18.5)  38 (12.1) 22 (7.0)   0 (0.0) 60 (18.6)  
(y)G         0.04      0.01 
1  18 (5.6)  6 (1.9) 11 (3.5)   4 (1.2) 14 (4.3)  
2  175 (54.2)  67 (21.3) 101 (32.2)   11 (3.4) 164 (50.8)  
3  130 (40.2)  69 (21.9) 60 (19.1)   5 (1.5) 125 (38.7)  
R         >0.05      >0.05 
0  282 (87.3)  127 (40.4) 148 (47.1)   18 (5.6) 264 (81.7)  
1  41 (12.7)  15 (4.8) 24 (7.6)   2 (0.6) 39 (12.1)  
UICC Staging        0.02      <0.001 
I  73 (22.6)  26 (8.3) 41 (13.1)   12 (3.7) 61 (18.9)  
II  71 (21.9)  28 (8.9) 42 (13.4)   5 (1.5) 66 (20.4)  
III  179 (55.5)  88 (28.0) 89 (28.3)   3 (0.9) 176 (54.5)  
NT         0.04      >0.05 
yes  73 (22.6)  40 (12.7) 31 (9.9)   5 (1.5) 68 (21.1)  
no  250 (77.4)  102 (32.5) 141 (44.9)   15 (4.6) 235 (72.8)  
Adjuvant Treatment       >0.05      0.03 
yes  156 (48.3)  73 (23.2) 80 (25.5)   5 (1.5) 151 (46.7)  
no  167 (51.7)  69 (22.0) 92 (29.3)   15 (4.6) 152 (47.1)  
cMK2 = cytoplasmic (MAPK)-activated protein kinase 2; nETV1 nuclear of Ets variant gene 1; SD = standard deviation; AC = adenocarcinomas; SCC = squamous cell 
carcinomas; R = resection margin; UICC = Union for International Cancer Control; NT = neoadjuvant therapy; AT = adjuvant therapy 
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Table 2. Contribution of nETV1, cETV1, nMK2 and cMK2 expression. 
 ETV1 MK2 
  nETV1 (%) 
 
cETV1 
 
(%) 
 
nMK2 
 
(%) 
 
cMK2 
 
(%) 
 
All High 20 (6.2) 30 (9.3) 143 (44.3) 142  (44.0) 
 
 
Low/Absent 303 (93.8) 293 (90.7) 171 (53.0) 
 
172 
 
 (53.3) 
 
 
NA 
 
0 
 
(0.0) 
 
0 
 
(0.0) 
 
9 
 
(2.7) 
 
9 
 
 (2.7) 
 
AC High 11 (5.7) 25 (13.0) 65 (33.8) 
 
104 
 
 (54.2) 
 
 
Low/Absent 181 (49.3) 167 (87.0) 122 (63.5) 
 
83 
 
 (43.2) 
 
 
NA 
 
0 
 
(0.0) 
 
0 
 
(0.0) 
 
5 
 
(2.7) 
 
5 
 
 (2.6) 
 
SCC High 9 (6.9) 5 (3.8) 78 (59.6) 38  (29.1) 
 
 
Low/Absent 122 (93.1) 126 (96.2) 49 (37.4) 
 
89 
 
 (67.9) 
 
 
NA 
 
0 
 
(0.0) 
 
0 
 
(0.0) 
 
4 
 
(3.0) 
 
4 
 
 (3.0) 
 
nETV1 = nuclear Ets variant gene 1;  cETV1 = cytoplasmic Ets variant gene 1; nMK2 = nuclear (MAPK)-activated protein kinase 2; cMK2 =cytoplasmic (MAPK)-activated 
protein kinase 2; AC = adenocarcinomas; SCC = squamous cell carcinomas. 
 
 
Significant association of cMK2 overexpression 
could be found for tumor staging (p<0.01), 
lymphnode status (p<0.01), UICC staging (p=0.02), 
tumor differentiation (p=0.04), neoadjuvant therapy 
(p=0.04), and tumor type (p<0.01). Evaluating nETV1, 
significant correlation was observed for tumor staging 
(p<0.01), lymphnode status (p<0.01), UICC staging 
(p<0.01), tumor type (p<0.01) and adjuvant therapy 
(p=0.03) (all Pearson’s Chi-square test) - Table 1.  
Analyzing the distribution of nETV1 
overexpressing cases, we found, that nETV1 
overexpression is significantly associated with a lower 
tumor stage (pT1: 13 (65%) cases; pT2: 2 (10%) cases; 
pT3: 5 (25%) cases; p<0.001). 
Univariate Survival Analysis  
Overall Survival - All Patients 
Evaluating the expression status of cMK2, 
nMK2, cETV1 and nETV1 for association with OS, the 
log-rank test was used to determine statistical 
significance. Kaplan-Meier analysis shows a 
significant correlation between high cMK2 expression 
and reduced patients’ survival. Patients with high 
expression of cMK2 showed a significantly lower 
(median = 14.5, mean = 24.9 months), while patients 
with low or absent cMK2 levels had longer OS 
(median = 20, mean = 35.35 months), p= 0.00949 
log-rank test (= Mantel-Haenszel test). Patients with 
high cMK2 expression had a 5 years OS at of 11.27% 
compared with 19.19% for patients with low or absent 
cMK2. No significant correlation of levels of nMK2 
expression and OS were found. Analyzing expression 
levels of nETV1 and cETV1, Kaplan-Meier analysis 
demonstrated a significant correlation with high 
nETV1 expression and improved patients’ OS. 
Patients with high nETV1 levels showed significantly 
better OS (median = 42.82, mean = 53.5 months), p= 
0.00507 log-rank test, while patients with low or 
absent nETV1 expression had a shorter OS (median = 
16.89, mean = 30 months). Patients with high nETV1 
expression had an OS at 5 years of 35% compared 
with 15.5% for patients with low or absent nETV1 
(Figure X). No significant correlation of cETV1 and OS 
could be found. Data for univariate analysis, using 
Cox proportional hazards model, is shown in Table 3. 
Disease Free Survival – All Patients 
The expression status of cMK2, nMK2, cETV1 
and nETV1 was also evaluated for association with 
DFS. No significance regarding DFS could be 
observed. 
Overall Survival – Subgroup AC  
In subgroup analysis of patients with AC, cases 
with high expression of cMK2 showed a significantly 
lower OS (median = 15.31, mean = 26.64 months), 
while patients with low or absent cMK2 levels had 
longer OS (median = 24.24, mean = 40 months), 
p=0.0156 log-rank test. Patients with high cMK2 
expression had an OS at 5 years of 13.5% compared 
with 21.69% for patients with low or absent cMK2 
(Figure X). Evaluating the expression of ETV1 in AC, 
patients with high nETV1 levels showed significantly 
better OS (median = 50.26, mean = 57.97 months) 
while patients with low or absent nETV1 expression 
had a shorter OS (median = 17.15, mean 32.17 
months). Log-rank p=0.015. Patients with high nETV1 
expression had an OS at 5 years of 27.27% compared 
with 17.68% for patients with low or absent nETV1 
(Figure X). No significant correlation of nMK2 and 
cETV1 and OS in the subgroup of AC could be found. 
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Disease Free Survival - Subgroup AC 
No significance regarding DFS could be 
observed in the subgroup of AC patients. 
Overall Survival – Subgroup SCC  
With p=0.06 for cMK2 and cETV1, respectively, 
statistical trends, but no statistical significance 
regarding OS could be observed in the subgroup of 
SCC (Figure X).   
Disease Free Survival – Subgroup SCC 
No significance regarding DFS could be 
observed in the subgroup of SCC patients. 
Multivariate Survival Analysis  
Using the Cox proportional hazards model for 
multivariable analysis was carried out to assess the 
prognostic value of cMK2 and nETV1 expression for 
both OS and DFS (Table 3 and 4). The following 
prognostic variables were included in the regression 
model: age, sex, UICC stage, tumor differentiation, 
resection margin, neoadjuvant- and adjuvant therapy. 
Overall Survival 
In multivariate analysis of AC tumors, high 
cMK2 expression was an independent negative 
prognostic factor for OS (p=0.04; RR 1.38, 1.01-1.89) 
(Table 3). Evaluating nETV1 expression in AC tumors 
with multivariate analysis, a nearly significant 
(p=0.05; RR 0.47, 0.22-1.00) decrease of 53% in risk in 
OS for patients with high nETV1 expression could be 
found (Table 4).  
 
Table 3. Univariate Cox regression analyses estimating the influence of cMK2 and nETV1 and clinicopathologic parameters on overall 
survival (OS) and disease free survival (DFS). 
  p-value univariate RR 95% CI    p-value univariate RR 95% CI 
Overall Survival      Disease Free Survival     
           
All      All     
cMK2  0.01 1.352 1.08 - 1.70  cMK2  0.076 1.23 0.98 - 1.55 
nETV1  0.006 0.491 0.30 - 0.82  nETV1  0.091 0.662 0.41 - 1.07 
(y)pT  < 0.001 1.484 1.23 - 1.70  (y)pT  < 0.001 1.411 1.23 - 1.62 
(y)pN  < 0.001 1.336 1.21 - 1.48  (y)pN  < 0.001 1.361 1.23 - 1.51 
UICC Staging  < 0.001 1.903 1.45 - 2.49  UICC Staging  < 0.001 1.739 1.33 - 2.28 
(y)pG  < 0.001 1.402 1.17 - 1.69  (y)pG  0.002 1.336 1.11 - 1.61 
R  0.92 1.017 0.73 - 1.42  R  0.579 1.1 0.79 - 1.54 
Age  < 0.001 0.976 0.97 - 0.99  Age  < 0.001 0.975 0.97 - 0.99 
Sex  0.0518 0.765 0.58 - 1.00  Sex  0.208 0.841 0.64 - 1.10 
NT  < 0.001 1.714 1.30 - 2.25  NT  < 0.001 1.77 1.35 - 2.33 
AT  < 0.001 0.623 0.50 - 0.78  AT  < 0.001 0.66 0.53 - 0.83 
           
AC      AC     
cMK2  0.016 1.445 1.07 - 1.95  cMK2  0.125 1.261 0.94 - 1.70 
nETV1  0.018 0.423 0.21 - 0.86  nETV1  0.102 0.571 0.29 - 1.12 
(y)pT  < 0.001 1.579 1.31 - 1.91  (y)pT  < 0.001 1.575 1.30 - 1.91 
(y)pN  < 0.001 1.389 1.22 - 1.58  (y)pN  < 0.001 1.384 1.21 - 1.60 
UICC Staging  < 0.001 1.927 1.36 - 2.73  UICC Staging  < 0.001 1.828 1.29 - 2.60 
(y)pG  < 0.001 1.566 1.20 - 2.04  (y)pG  0.002 1.508 1.16 - 1.96 
R  0.699 1.092 0.70 - 1.71  R  0.435 1.196 0.76 - 1.88 
Age  0.001 0.979 0.97 - 0.99  Age  < 0.001 0.976 0.96 - 0.99 
Sex  0.532 0.887 0.61 - 1.29  Sex  0.713 0.932 0.64 - 1.36 
NT  < 0.001 1.812 1.27 - 2.58  NT  < 0.001 2.087 1.46 - 2.98 
AT  0.008 0.676 0.51 - 0.90  AT  0.032 0.728 0.54 - 0.97 
           
SCC      SCC     
cMK2  0.064 1.447 0.98 - 2.14  cMK2  0.06 1.44 0.98 - 2.12 
nETV1  0.199 0.621 0.30 - 1.29  nETV1  0.437 0.76 0.38 - 1.52 
(y)pT  0.002 1.3 1.12 - 1.66  (y)pT  0.029 1.241 1.02 - 1.51 
(y)pN  < 0.001 1.366 1.14 - 1.64  (y)pN  < 0.001 1.518 1.25 - 1.85 
UICC Staging  0.005 1.831 1.20 - 2.80  UICC Staging  0.0256 1.62 1.06 - 2.48 
(y)pG  0.01 1.474 1.09 - 1.99  (y)pG  0.03 1.386 1.03 - 1.86 
R  0.652 0.888 0.53 - 1.49  R  0.883 0.96 0.57 - 1.63 
Age  0.002 0.973 0.96 - 0.99  Age  0.006 0.976 0.96 - 0.99 
Sex  0.022 0.631 0.43 - 0.93  Sex  0.052 0.674 0.45 - 1.00 
NT  0.036 1.6 1.03 - 2.48  NT  0.079 1.488 0.96 - 2.32 
AT  < 0.001 0.495 0.34 - 0.71  AT  < 0.001 0.474 0.33 - 0.69 
RR = relative risk; CI = confidence interval; cMK2 = cytoplasmic (MAPK)-activated protein kinase 2; nETV1 nuclear of Ets variant gene 1; AC = adenocarcinomas; SCC = 
squamous cell carcinomas; R = resection margin; UICC = Union for International Cancer Control; NT = neoadjuvant therapy; AT = adjuvant therapy 
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Table 4. Multivariate Cox regression analyses estimating the influence of cMK2 and nETV1 and clinicopathologic parameters on overall 
survival (OS) and disease free survival (DFS). 
  p-value multivariate RR 95% CI    p-value multivariate RR 95% CI 
           
Overall Survival           
           
All           
cMK2  0.16 1.187 0.93 - 1.51  nETV1  0.091 0.625 0.36 - 1.08 
UICC Staging  0.02 1.443 1.05 - 1.98  UICC Staging  0.056 1.365 0.99 - 1.88 
(y)pG  0.07 1.201 0.98 - 1.47  (y)pG  0.09 1.187 0.97 - 1.45 
R  0.81 1.044 0.73 - 1.48  R  0.588 1.098 0.78 - 1.54 
Age  <0.001 0.981 0.97 - 0.99  Age  <0.001 0.979 0.97 - 0.99 
Sex  0.35 0.874 0.66 -1.16  Sex  0.387 0.885 0.67 - 1.17 
NT  0.04 1.352 1.01 - 1.81  NT  0.005 1.491 1.13 - 1.97 
AT  0.08 0.793 0.61 - 1.02  AT  0.089 0.803 0.62 - 1.03 
           
AC           
cMK2  0.043 1.381 1.01 - 1.89  nETV1  0.053 0.467 0.22 - 1.01 
UICC Staging  0.087 1.460 0.95 - 2.25  UICC Staging  0.218 1.31 0.85 - 2.01 
(y)pG  0.058 1.324 0.99 - 1.77  (y)pG  1.267 0.107 0.95 - 1.69 
R  0.891 1.033 0.65 - 1.65  R  0.487 1.179 0.74 - 1.88 
Age  0.103 0.988 0.97 - 1.00  Age  0.025 0.984 0.97 - 1.00 
Sex  0.769 1.062 0.71 - 1.57  Sex  0.972 0.888 0.66 - 1.44 
NT  0.034 1.498 1.03 - 2.18  NT  1.626 0.01 1.12 - 2.36 
AT  0.341 0.848 0.60 -1.19  AT  0.888 0.488 0.64 - 1.24 
           
SCC           
cMK2  0.336 1.238 0.80 - 1.91  nETV1  0.628 1.228 0.54 - 2.82 
UICC Staging  0.526 1.177 0.71 - 1.95  UICC Staging  0.283 1.334 0.788 - 2.26 
(y)pG  0.05 1.402 0.99 - 1.98  (y)pG  0.041 1.431 1.02 - 2.02 
R  0.488 1.223 0.69 - 2.16  R  0.476 1.225 0.70 - 2.14 
Age  0.01 0.975 0.96 - 0.99  Age  0.009 0.976 0.96 - 0.99 
Sex  0.06 0.671 0.44 - 1.02  Sex  0.15 0.742 0.49 - 1.11 
NT  0.725 1.097 0.66 - 1.83  NT  0.188 1.359 0.86 - 2.14 
AT  0.016 0.599 0.39 - 0.91  AT  0.011 0.584 0.39 - 0.89 
           
Disease Free Survival          
           
All           
cMK2  0.755 1.04 0.81 - 1.33  nETV1  0.464 0.826 0.49 - 1.39 
UICC Staging  0.071 1.34 0.98 - 1.84  UICC Staging  0.084 1.329 0.96 - 1.84 
(y)pG  0.084 1.20 0.98 - 1.47  (y)pG  0.099 1.184 0.97 - 1.45 
R  0.615 1.094 0.91 - 1.55  R  0.38 1.17 0.83 - 1.64 
Age  < 0.001 0.98 0.97 - 0.99  Age  <0.001 0.979 0.97 - 0.99 
Sex  0.752 0.955 0.72 - 1.27  Sex  0.945 0.99 0.75 - 1.31 
NT  0.016 1.435 1.07 - 1.93  NT  0.004 1.515 1.14 - 2.00 
AT  0.084 0.80 0.61 - 1.03  AT  0.11 0.812 0.63 - 1.05 
           
AC           
cMK2  0.403 1.145 0.83 - 1.57  nETV1  0.216 0.637 0.31 - 1.30 
UICC Staging  0.067 1.503 0.97 - 2.33  UICC Staging  0.144 1.38 0.90 - 2.12 
(y)pG  0.092 1.282 0.96 - 1.71  (y)pG  0.138 1.244 0.93 - 1.66 
R  0.82 1.056 0.66 - 1.70  R  0.494 1.176 0.74 - 1.87 
Age  0.02 0.983 0.97 - 0.99  Age  0.006 0.981 0.97 - 0.99 
Sex  0.70 1.082 0.73 - 1.61  Sex  0.858 1.036 0.70 - 1.53 
NT  0.004 1.754 1.20 - 2.60  NT  0.002 1.846 1.27 - 2.70 
AT  0.488 0.887 0.63 - 1.24  AT  0.597 0.914 0.65 - 1.28 
           
SCC           
cMK2  0.297 1.267 0.81 - 1.98  nETV1  0.406 1.406 0.63 - 3.14 
UICC Staging  0.793 0.932 0.55 - 1.57  UICC Staging  0.649 1.135 0.66 - 1.96 
(y)pG  0.072 1.364 0.97 - 1.91  (y)pG  0.044 1.419 1.01 - 1.99 
R  0.228 1.443 0.80 - 2.62  R  0.17 1.506 0.84 - 2.70 
Age  0.02 0.977 0.96 - 0.99  Age  0.018 0.978 0.96 - 1.00 
Sex  0.101 0.70 0.45 - 1.07  Sex  0.235 0.775 0.51 - 1.18 
NT  0.684 0.895 0.52 - 1.53  NT  0.609 1.129 0.71 - 1.80 
AT  0.004 0.53 0.34 - 0.82  AT  0.004 0.533 0.35 - 0.82 
RR = relative risk; CI = confidence interval; cMK2 = cytoplasmic (MAPK)-activated protein kinase 2; nETV1 nuclear of Ets variant gene 1; AC = adenocarcinoma; SCC = 
squamous cell carcinomas; R = resection margin; UICC = Union for International Cancer Control; NT = neoadjuvant therapy; AT = adjuvant therapy 
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 No significant correlation of cMK2, nMK2, 
cETV1 and nETV1 and OS in the groups of all and 
SCC patients could be found. 
Disease Free Survival – All Patients, AC and SCC 
Patients 
No significance regarding DFS could be 
observed for cMK2, nMK2, cETV1 and nETV1 in the 
groups of all, AC and SCC patients. 
Discussion 
Beside recent improvements in multimodal 
treatment modalities, prognosis for patients with 
esophageal cancer remain poor. In this study, IHC 
was performed to investigate the clinical relevance of 
MK2 and ETV1 in esophageal cancer patients. We 
demonstrated that overexpression of cMK2 in AEC is 
associated with significantly poorer OS and that 
overexpression of nETV1 in EAC is associated with 
significantly better OS.  
Yamamoto et al. could show an expression of 
ETV1 in 61% of cases of gastric cancer. Furthermore, 
ETV1 correlated significantly with patients’ survival, 
tumor staging, lymphnode status und metastasis. The 
focus of that study was on the connection between the 
expression of matrix metalloproteinases (MMP7) and 
ETV4/PEA3, explaining the strong tendency to tumor 
invasion and metastasis [26].  
In this underlying study we found cytoplasmic 
overexpression of MK2 in 44.0% and nuclear 
overexpression in 44.3% of all cases. Cytoplasmic and 
nuclear expression of ETV1 was found in only 9.3% 
and 6.2% of cases, respectively. Our data go in good 
accordance with the in-vivo and in-vitro findings from 
Jahnknecht R., describing MK2 and its suppressive 
effect on ETV1 [6].  
Overexpression of cMK2 correlated with tumor 
type, higher tumor stage, positive lymph node status 
and tumor differentiation. For nETV1 we found 
significant correlation with tumor staging, 
lymphnode status, UICC staging, tumor type and 
adjuvant therapy. Furthermore, supporting our 
hypothesis, that ETV1 is strongly suppressed by MK2 
in higher tumor stages, we found, that nETV1 
overexpression is significantly associated with a lower 
tumor stage in our patients’ collective. 
Keld et al. examined the expression of ETV1 in 
EAC, not discriminating between cytoplasmic and 
nuclear expression, and found higher expression in 
EAC samples than in normal tissue and an association 
with metastatic disease [19].  
In contrast, we found cytoplasmic and nuclear 
overexpression of ETV1 in only 13.0% and 5.7% of 
EAC patients, respectively. Even more surprising, 
patients in our study seem to benefit from nuclear 
overexpression of ETV1, showing a significantly 
better overall survival than patients without ETV1 
overexpression. In the same subgroup of patients 
(EAC) we observed a significantly impaired overall 
survival of patients with cytoplasmic overexpressing 
of MK2. These findings might be supported by data 
from Jahnknecht R., reporting a suppressive effect in 
the expression of ETV1, as well [6].  
One of the main reasons for the development of 
EAC is gastroesophageal reflux disease (GERD). EAC 
typically develops in intestinal metaplasia (Barretts’ 
disease) caused by constant inflammation due to the 
washback of stomach content into the esophagus. 
Based on that constant, local inflammation and later 
due to inflammatory tumor response, upregulated 
and overexpressed MK2 might lead to downreg-
ulation of ETV1. This hypothesis is supported by our 
findings, that ETV1 overexpression correlates with a 
lower tumor stage, is frequently found in high-grade 
dysplasia and is therefore significantly associated 
with an increased overall survival.  
Investigating the role of ETV1 in ESCC, the 
recently published study from Yuen et al. found no 
significantly difference between non-tumor 
esophageal epithelium and ESCC specimens. 
Furthermore, Yuen et al. described no overexpression 
of ETV1 and no positive correlation between ETV1 
and clinicopathological parameters in their study [10]. 
These findings go in good accordance with our data, 
due to no correlation of cytoplasmic or nuclear ETV1 
overexpression and clinical parameters could be 
observed as well. Furthermore, our data on 
expression of ETV1 in ESCC support our hypothesis, 
that the suppressing effect of MK2 on ETV1, based on 
inflammation is relevant in EAC, but not in ESCC. 
Conclusion 
The oncogenic potential of ETV1 is proven for a 
number of malignancies [12, 16, 17, 27]. Based on the 
data from Keld et al. and Yuen et al. the knowledge 
about the oncogenic role of ETV1 in esophageal cancer 
is limited. Even though interactions due to structural 
similarities with PEA3 and other related ETS family 
members could be shown, impact on patients and 
details of biological mechanisms are not fully 
understood yet. Until now, only few data exist on the 
clinical role of ETV1 in patients suffering from 
esophageal cancer.  
In this study, multivariate analysis has shown 
that the overexpression of cMK2 and nETV1 are 
independent prognostic factors.  
The observations of this study underline the 
importance of further investigations in the field of the 
ETV family and its role in the MAPKinase pathway as 
a potential therapeutic onset. 
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Figure 2. (A and B) Positive staining of an esophageal adenocarcinoma specimen with MK2 antibody ab63574 and blue counterstaining of nuclei with hematoxylin. (C 
and D) Positive staining of an esophageal adenocarcinoma specimen (tissue micro array) with ETV1 antibody ab81086. Left panels (A and C) 40x magnification, right 
panels (B and D) 400x magnification. 
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